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Recent studies indicate that the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) can be used to engraft T cell costimulatory
molecules onto tumor cell membranes, potentially circumventing the need for genetic manipulation of the cells for development of cell- or
membrane-based tumor vaccines. Here, we show that a related lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA3-DTDA, which has three NTA
moieties in its headgroup instead of one) is several-fold more effective than NTA-DTDA at promoting stable His-tagged protein engraftment.
IAsys biosensor studies show that binding of His-tagged B7.1 (B7.1-6H) to NTA3-DTDA-containing membranes, exhibit a faster on-rate and a
slower off-rate, compared to membranes containing NTA-DTDA. Also, NTA3-DTDA-containing liposomes and plasma membrane vesicles
(PMV) engrafted with B7.1-6H and CD40-6H exhibit greater binding to T cells, in vitro and in vivo. Engrafted NTA3-DTDA-containing PMV
encapsulated cytokines such as IL-2, IL-12, GM-CSF and IFN-g, allowing targeted delivery of both antigen and cytokine to T cells, and
stimulation of antigen-specific T cell proliferation and cytotoxicity. Importantly, use of B7.1-CD40-engrafted PMV containing IL-2 and IL-12 as a
vaccine in DBA/2J mice induced protection against challenge with syngeneic tumor cells (P815 mammary mastocytoma), and regression of
established tumors. The results show that stable protein engraftment onto liposomal membranes using NTA3-DTDA can be used to simultaneously
target associated antigen, costimulatory molecules and cytokines to T cells in vivo, inducing strong anti-tumor responses and immunotherapeutic
effect.
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The transfection of tumor cells to induce expression of T cell
costimulatory molecules and/or cytokines, is a potentially viable
approach for the development of cell-based tumor vaccines and0005-2736/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2005.09.003
Abbreviations: PMV, Plasma membrane vesicles; Streptavidin-FITC,
Fluorescein isothiocyanate-conjugated streptavidin; POPC, Palmitoyl-oleoyl-
phosphatidylcholine; DMPC, Dimyristoyl-phosphatidylcholine; NTA-DTDA,
nitrilotriacetic acid ditetradecylamine; PEG400, Polyethyleneglycol-400; FITC-
DHPE, N-(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-
phospho-ethanolamine, triethylammonium salt; PE-PEG2000, 1,2-dimyristoyl-
sn-glycero-3-phosphoethanolamine-N-polyethylene-glycol-2000
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E-mail address: Joseph.Altin@anu.edu.au (J.G. Altin).immunotherapies [1–3]. Protective immunity has notably been
reported following vaccination of animals with tumor cells that
have been transfected to express different costimulatory and
adhesion molecules such as B7.1 (CD80), B7.2 (CD86), CD40,
and ICAM-1 [4–8], and different immunostimulatory cytokines
such as GM-CSF, IL-2 and IL-12 [9–12]. The use of genetically
modified tumor cells as vaccines, however, is impractical, and
may present safety concerns for widespread clinical use.
Of importance to the development of immunotherapies is the
fact that, when used as a vaccine or adjuvant, cytokine that is
associated with liposomal structures can often exhibit enhanced
efficacy and reduced toxicity, compared to ‘‘free’’ cytokine [13–
15]. For example, liposome-associated IL-2 was found to be
several orders of magnitudemore potent at promoting survival of
the murine T cell clone D10 in vitro [16], and mice vaccinated1716 (2005) 104 – 116
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response and less toxicity, if IL-2 is co-administered as a
liposome-associated, rather than as a ‘‘free’’ or soluble form
[17–20]. Interestingly, the delivery of cytokines to the site of
antigen presentation also is purported to enhance systemic
immune protection [21,22]. The targeting of antigenic, costimu-
latory and cytokine-mediated signals to Tcells in vivo, therefore,
could well have synergistic effects in inducing tumor immunity.
In previous studies, we showed that recombinant forms of
the costimulatory molecules B7.1 and CD40 bearing a histidine
tag can be anchored or ‘‘engrafted’’ onto the surface of
liposomes and tumor cell-derived plasma membrane vesicles
(PMV), following incorporation of the chelator-lipid nitrilo-
triacetic acid ditetradecylamine (NTA-DTDA). The engrafted
molecules enable such modified membranes to be targeted to T
cells through the cognate receptor interactions CD86-CD28
and CD40-CD40L [16,23]. To further develop this approach, in
the present work, we report the properties of a novel chelator-
lipid, NTA3-DTDA, which is related to NTA-DTDA, but
contains three NTA moieties in its headgroup instead of one
(see Fig. 1). IAsys biosensor studies show that His-tagged
proteins bind more strongly to membranes containing NTA3-Fig. 1. The structure of NTA (nitrilotriacetic acid) ditetradecylamine (NTA-DDTDA than to membranes containing NTA-DTDA. When
incorporated into P815 cell-derived PMV, NTA3-DTDA
enabled stable engraftment of B7.1 and CD40. Engrafted
PMV containing IL-2, IL-12, GM-CSF and IFN-g allowed
targeted delivery of these cytokines to T cells and induced
effective anti-tumor responses when used as vaccines.
2. Materials and methods
2.1. Reagents
Paraformaldehyde was obtained from BDH Chemicals (Kilsyth, Victoria,
Australia). RPMI 1640 medium was obtained from Gibco-BRL (Invitrogen,
Melbourne, Australia). Fetal calf serum (FCS) was obtained from Trace,
Biosciences (Noble Park, Victoria, Australia). Sulfo-NHS-LC-Biotin and
fluorescein isothiocyanate-conjugated streptavidin (streptavidin-FITC) was
obtained from Pierce (Rockford, IL). Dimyristoyl-phosphatidylcholine (DMPC),
1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), h-mercaptoethanol and
polyethylene glycol-400 (PEG400) were obtained from Sigma-Aldrich (Castle
Hill, N.S.W., Australia). N-(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine, triethyl-ammonium salt (FITC-DHPE)
was from Molecular Probes (Eugene, OR), and 1,2-dimyristoyl-sn-glycero-
3-phosphoethanolamine-N-polyethylene-glycol-2000 (PE-PEG2000) was from
Avanti Polar Lipids Inc. The chelator-lipid 3(nitrilotriacetic acid)-ditetradecy-TDA) and 3NTA (nitrilotriacetic acid) ditetradecylamine (NTA3-DTDA).
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groups covalently linked to two ditetradecylamine (DTDA) chains was
synthesized essentially as described [24], but with additional steps to covalently
couple a NTA group onto each carboxyl group of the NTA-DTDA, to produce
NTA3-DTDA (J.G. Altin, manuscript in preparation). NiSO4 was used for all
additions of Ni2+ to buffers.
2.2. Mice and cells
Female or male DBA/2J mice (H-2d), were used for isolation of splenic T
cells for use in binding assays using flow cytometry, for T cell proliferation and
cytotoxicity assays, and for vaccinations and assessment of tumor growth in vivo.
The mice were used at 6–8 weeks of age and were obtained from the Animal
Breeding Establishment, John Curtin School of Medical Research (JCSMR),
Australian National University (ANU), Canberra. For isolation of splenic Tcells,
spleens were removed and dissociated into single cell suspension, the red cells
were removed by hypotonic lysis and centrifugation, and the Tcells then purified
by nylon wool adherence, essentially as described [16].
Murine P815 mastocytoma [DBA/2J (H-2d)] cells were obtained from Dr.
H. Warren (John Curtin School of Medical Research, ANU). The murine CD4+
T cell clone D10 [AKR/J (H-2k)] specific for conalbumin, was obtained from
Dr. B. van Leeuwen (School of Biochemistry and Molecular Biology, ANU).
All cells were cultured in complete medium consisting of RPMI 1640
containing 10% FCS and 2 mM glutamine, and maintained at 37 -C in an
incubator with an atmosphere of 5% CO2. The D10 cells also were routinely
grown in the presence of 50 IU/ml murine IL-2 as described [25]. Expression of
CD28 and CD40L on D10 cells was upregulated by pre-incubation of the cells
with the TCR activation idiotype-specific mAb 3D3 (5 Ag/ml) for 18–24 h, as
previously described [23].
2.3. Recombinant proteins
Recombinant human IL-2 (Proleukin) was obtained from EuroCetus
(Amsterdam, The Netherlands). Recombinant murine IL-12, IFN-g and GM-
CSF were obtained from PeproTech Inc. (Rockey Hill, NJ). Where indicated,
recombinant cytokines were biotinylated by reacting with sulfo-NHS-LC-biotin
as described [25]. Recombinant forms of the extracellular regions of murine
B7.1 (CD80) and CD40, denoted B7.1-6H, and CD40-6H, respectively; and the
extracellular region of the human erythropoietin receptor (EPOR), denoted
EPOR-6H, each with a hexahistidine (6H) tag at the carboxy terminal, were
expressed using the baculovirus expression system with the proteins being
purified from the culture supernatants of virus-infected High-5 cells as
described [26]. Recombinant proteins were stored at 20 -C in PBS at a
concentration of 0.2–0.6 mg/ml; the proteins were thawed at 37 -C and
vortexed gently prior to use in each experiment.
2.4. IAsys biosensor studies
Membranes containing DMPC, POPC and either NTA-DTDA or NTA3-
DTDA as indicated, were deposited onto the IAsys sensing surface of an IAsys
biosensor dual-cell cuvette from a suspension of liposomes exactly as described
[24]. After membrane deposition, the cuvette was washed 4 times with PBS and
4 times with distilled water, before again washing with PBS and allowing the
instrument to equilibrate for 5–10 min to achieve a stable baseline before use in
binding studies. Binding experiments were carried out at 25 -C in PBS using the
indicated test membrane in one cell and a control membrane containing 95
mol% DMPC and 5 mol% POPC in the other cell. The contents of each cell were
stirred continuously (80 cycles/s) and binding to the sensing surface in each cell,
was measured at 2 s intervals in units of arc seconds (arc s). Proteins were added
to the test cell from stock solutions made in PBS to give the appropriate final
protein concentration. Binding of B7.1-6H to membranes was monitored for 5
min; the contents of each cell were then replaced by washing 4 times with PBS,
and dissociation then monitored for 20 min. For analysis of binding data, the
signal of the control cell was subtracted from that of the test cell to remove the
bulk refractive index change and the effect of any non-specific binding.
Kinetic constants were evaluated from profiles for the binding of B7.1-6H
to membranes containing either NTA-DTDA or NTA3-DTDA using the ‘‘FastFit’’ program. kobs was calculated from a single exponential fit of the binding
phase, and kon was determined from the gradient of the plot of kobs versus
protein concentration which approximated a straight line. As a single
exponential dissociation did not adequately fit the dissociation data, and koff
when determined from the y-intercept of the plot of kobs versus protein
concentration was ¨103, as suggested by the manufacturer, therefore, double
exponential fitting was used to calculate the fast and slow koff components. The
dissociation constant was determined using the expression Kd=koff/kon. Other
details have been described [24].
2.5. Plasma membrane vesicles
2.5.1. Preparation
PMV were prepared from murine P815 mastocytoma as described [16,27].
Briefly, cultured P815 cells (1108) were washed twice with PBS, and the
cells were suspended in homogenization buffer [10 mM sodium phosphate (pH
7.4) containing 30 mM NaCl, 1 mM MgCl2, and 0.02% NaN3], and
homogenized by brief sonication at 4 -C. The cell lysate was then layered
over a solution of 41% sucrose and then centrifuged (95,000g) for 1 h at 4 -C.
The PMV were collected from the interfacial band and washed twice in
homogenization buffer by centrifugation (95,000g, 20 min, 4 -C). Stock
PMV suspensions were stored at 20 -C, and briefly re-sonicated prior to use
in each experiment.
2.5.2. Incorporation of NTA3-DTDA and cytokine
Liposomes were prepared from a mixture of POPC, NTA-DTDA and FITC-
DHPE (in molar ratio of 78:20:2), or POPC, NTA3-DTDA, and FITC-DHPE
(in molar ratio of 96:2:2) dissolved in ethanol/chloroform (3:1). For some
experiments, the tracer lipid BODIPY-PC (Molecular Probes) was used instead
of FITC-DHPE; BODIPY-PC has a higher quantum yield and was found to
give a higher level of cell fluorescence following the binding of liposomes (not
shown). For functional studies, the tracer lipid was omitted from the lipid
mixtures. Lipid mixtures were dried under a stream of nitrogen gas, and
liposomes were produced by rehydrating the desiccated lipids in 100 Al PBS
containing Ni2+ (200 AM Ni2+ for mixtures containing NTA-DTDA and 60 AM
Ni2+ for mixtures containing NTA3-DTDA), and suspending to a total lipid
concentration of 1 mM. Where indicated, cytokines were incorporated with
liposomes by rehydrating the lipids in 100 Al PBS containing 50 ng IL-2, IL-12,
GM-CSF or IFN-g, in addition to Ni2+. Liposome suspensions (with or without
cytokines) were then produced as described [16]. The resulting liposomes were
then fused with PMV by mixing 100 Al of the indicated liposome suspension
with 100 Al of PMV (1107 cell equivalents); and then adding 15% PEG400,
and immediately diluting the composite vesicles in PBS. For PMV containing
cytokine, the vesicles were purified by size exclusion chromatography on
Sephadex columns (G25 for PMV containing IL-2, GM-CSF and IFN-g, and
G100 for PMV containing IL-12) (Pharmacia Biotech, Uppsala, Sweden) with
PBS, to remove any unincorporated cytokine.
To assess the efficiency of incorporation of cytokines into the modified
PMV, the cytokines were biotinylated and then associated with liposomes and
fused with PMV (as described above). The modified PMV were then subjected
to size-exclusion chromatography, and both the vesicle-incorporated and
unincorporated-cytokine fraction were eluted and collected separately. Each
fraction was then concentrated using a Centricon-10 (Millipore, Bedford, MA)
microconcentrator, and run on SDS-PAGE (5–15% acrylamide gel) under
reducing conditions. The biotinylated proteins were then electrophoretically
transferred onto a nitrocellulose membrane, and detected by enhanced
chemiluminescence (ECL) after probing the membrane with streptavidin-
HRP as described [25].
2.5.3. Engraftment of costimulatory molecules
For engraftment of recombinant protein(s) onto the vesicle surface, purified
PMVcontaining incorporated NTA-DTDAor NTA3-DTDA, andwith or without
encapsulated cytokine(s) as indicated, were incubated with 200 Ag/ml of the
appropriate 6H-tagged protein in a 0.5-ml PCR tube at room temperature for 1 h.
2.5.4. Binding of engrafted plasma membrane vesicles to cells in vitro
Splenic T cells were suspended (1107 cells/ml) in RPMI 1640 medium
containing 10% FCS plus 10 mM HEPES (pH 7.4), and the cells then aliquoted
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cells/well. The cells were incubated with engrafted PMV corresponding to
2105 cell equivalents for 1 h on ice with frequent gentle vortexing of the
plate. After the incubation, unbound vesicles were removed by washing the
cells twice with PBS containing 0.1% BSA (PBS-BSA). The cells were then
fixed with 2% paraformaldehyde in PBS, and analysed for FITC-fluorescence
by flow cytometry, as previously described [16].
2.6. Targeting engrafted liposomes and PMV to cells in vivo
Male or female DBA/2J mice were injected in the hind footpad using a
26-gauge needle and 1 ml syringe with conventional liposomes (CL) composed
of POPC, NTA3-DTDA and BODIPY-PC (molar ratio of 98:1:1, total lipid
0.5 mM), stealth liposomes (SL) composed of POPC, NTA3-DTDA,
BODIPY-PC and PE-PEG2000 (molar ratio; 93:1:1:5, total lipid 0.5 mM), or
modified PMV (2106 cell equivalents), each engrafted with either EPOR-6H
or B7.1-6H and CD40-6H. After 14 h, the mice were euthanised and the
draining and non-draining popliteal lymph nodes isolated. After removal of the
RBC by hypotonic lysis, the lymphocytes were stained with biotinylated CD3(
mAb and streptavidin-PE, and then examined for BODIPYand PE-fluorescence
by flow cytometry using a FacsSort (Becton Dickinson) as described [26]. The
results of independent experiments are presented as the mean fluorescence
intensity from peak-to-peak relative to the indicated controlT the standard error
of the mean (S.E.M.).
2.7. T cell proliferation and cytotoxicity assays
Purified splenic (DBA/2J) T cells were suspended in complete growth
medium (2104 cells/50 Al/well) and cultured for 4 days in a 96-well flat
bottom plate (Cell Wells, Corning, NY) in the presence of g-irradiated (5000
rad) P815 tumor cell-derived PMV engrafted with recombinant proteins and
containing encapsulated cytokines, at 37 -C in an atmosphere of 5% CO2. After
4 days culture, the cells were pulsed for 6–8 h with 1 ACi of [3H]-thymidine
per well, for measurement of T cell proliferation as described [26].
Syngeneic DBA/2J mice were immunised subcutaneously with either PBS
(control) or g-irradiated (5000 rad) P815 cell-derived PMV (2105 cell
equivalents) engrafted with recombinant proteins and containing encapsulated
IL-2. Spleens were removed from mice 14 days after immunisation, and the T
lymphocytes (effector cells) were isolated (as above) and co-cultured (at 1105
cells/well) with 1105 g-irradiated (5000 rad) native P815 cells. After 5 days
of co-culture, the cytolytic activity of the effector cells was assessed in a
standard 51Cr-release assay.
2.8. Assessment of tumor growth and regression in vivo
Mice (DBA/2J) were immunised subcutaneously with either PBS (control)
or g-irradiated syngeneic P815 cell-derived PMV (2105 cell equivalents)
containing engrafted recombinant proteins and encapsulated cytokines as
indicated. After 14 days, the mice were challenged with 1105 native P815
cells by subcutaneous injection, and tumor growth and survival was monitored
with time as described [16]. For assays of tumor regression, mice were injected
subcutaneously with 1105 native P815 cells, and two weeks later, the mice
were vaccinated three times at 1-week intervals with g-irradiated P815 cell-
derived PMV (2105 cell equivalents) containing encapsulated IL-2 and IL-12
(50 ng each). Tumor size in each group of mice was monitored, and the survival
time of the animals recorded.
3. Results
3.1. Kinetics of binding of B7.1-6H to membranes containing
NTA-DTDA or NTA3-DTDA
To assess the potential of the novel chelator lipid NTA3-
DTDA to be useful for the stable anchoring of proteins onto
membranes, the binding of a 6His-tagged protein (B7.1-6H) to
membranes containing either NTA3-DTDA or NTA-DTDAwascompared in studies with the IAsys biosensor similar to those
described [24]. Preliminary experiments indicated that, when
used at the same molar ratio of carrier to chelator lipid (i.e.,
molar ratio of carrier lipid/chelator lipid of 10:1), NTA3-DTDA
was significantly more potent than NTA-DTDA, at promoting
stable binding of His-tagged proteins to membranes (not
shown). This could be due to the fact that at under these
conditions, the NTA3-DTDA provides a 3-fold higher density
of NTA moieties on the membrane surface, compared to NTA-
DTDA (Fig. 1). To better characterise the strength of the
interaction between 6His-tagged proteins with membranes
containing NTA3-DTDA, therefore, the binding of B7.1-6H
to membranes on the IAsys biosensor was examined at a range
of different B7.1-6H concentrations, and at a concentration of
NTA3-DTDA and NTA-DTDA in the membrane that gives the
same effective density of NTA groups.
Membranes containing DMPC and POPC (control mem-
brane), and DMPC and POPC plus 10 mol% NTA-DTDA
(test membrane), were deposited separately in the cells of an
IAsys biosensor dual-cell cuvette as described [24]. After
equilibration of the system, a different concentration of B7.1-
6H (in the range of 20–1000 nM) was added to each cell of
the cuvette, and binding to each membrane was monitored
with the biosensor for 5 min. Substantial binding of B7.1-6H
occurred to the test membrane, but little if any binding
occurred to the control membrane. The contents of the cuvette
were then replaced by washing 4 times with PBS, and the
dissociation phase was monitored for 20 min. The bound
protein was then removed by 4 washes with 500 mM
imidazole before equilibrating in PBS and adding a different
concentration of B7.1-6H. Similar experiments were per-
formed with membranes containing 3.3 mol% NTA3-DTDA
(instead of 10 mol% NTA-DTDA), deposited in the test cell.
Overlayed difference plots for the binding (and dissociation)
of the different concentrations of B7.1-6H to NTA-DTDA-
and to NTA3-DTDA-containing membranes as monitored
with the IAsys biosensor are shown in Fig. 2A and B,
respectively. It can be seen that binding of B7.1-6H to both
membranes is concentration-dependent, exhibiting saturation
kinetics with near-maximal binding occurring at ¨1 AM and
1–2 AM B7.1-6H for membranes containing NTA-DTDA and
NTA3-DTDA, respectively. An analysis of the binding profile
for each concentration of B7.1-6H using the Fast Fit program,
indicated that the binding data could generally be fitted to a
single exponential expression, for each type of membrane.
While some deviation from the single exponential was seen at
protein concentrations >200 nM (presumably reflecting re-
binding and/or complex binding events) these deviations were
relatively small and were considered not to significantly affect
estimates of the binding constants. A plot of the observed rate
constants (kobs, s
1) against the concentration of B7.1-6H
approximated a straight line (see Fig. 2C), with the line of
best fit revealing that B7.1-6H binds with an on-rate
(kon=slope of the plot) of 2.62T0.06104 M1 s1 for
NTA-DTDA-containing membranes, and 1.55T0.08104
M1 s1, for NTA3-DTDA-containing membranes. Similarly,
the line of best fit revealed the off-rate (koff= intercept with
Fig. 2. Kinetics for binding of 6His-tagged proteins to membranes containing
either NTA-DTDA or NTA3-DTDA. Membranes containing DMPC and POPC
(control cell), and membranes containing DMPC and POPC plus either 10
mol% NTA-DTDA or 3.3 mol% NTA3-DTDA (test well) were each deposited
in the separate wells of an IAsys biosensor cuvette. After equilibration of the
system in PBS, the indicated concentration of B7.1-6H in the range of 10 nM to
1 AMwas added to both the test and control wells. The binding and dissociation
phase for the interaction of B7.1-6H with each membrane was then monitored
with the biosensor for 5 and 20 min, respectively. Difference plots (test cell
minus control profiles) for the interaction of each concentration of B7.1-6H
with the NTA-DTDA-containing membrane is shown panel A, and those for the
interaction of B7.1-6H with NTA3-DTDA-containing membranes are shown in
panel B. The value of kobs for the binding curve for each concentration of B7.1-
6H to the membranes was obtained using the linearization method (Fast Fit
program), and each value for the respective membrane containing either NTA-
DTDA or NTA3-DTDA was then plotted against the concentration of protein
(C). For each membrane type the plot of kobs against protein concentration
gives a straight line; the slope represents kon, the koff for the interactions were
determined from the dissociation phase (see text). Error bars show the SEs from
three separate experiments at each concentration.
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membrane was ¨103 s1.
According to IAsys, koff values in the range 10
3 to 105
s1 need to be determined from the dissociation phase.
Therefore, for each B7.1 concentration the koff was determined
by extrapolating the dissociation data to the base line by curve
fitting using the Fast Fit program (not shown). At eachconcentration, dissociation phases were best described by two
dissociation components, one having a relatively fast off-rate
(¨105 s1), and the other having an off-rate one or two orders
of magnitude lower, especially for membranes containing
NTA3-DTDA. A summary of the on-rates, off-rates, the
contribution or extent of each binding component, stability or
half-life (T1/2), and apparent dissociation constants for the
interaction of B7.1-6H with NTA-DTDA and NTA3-DTDA-
containing membranes is shown in Table 1. The results indicate
that the off-rates were concentration-dependent, with the least
stable binding (shortest T1/2) occurring at the highest concen-
tration of B7.1-6H. This was more pronounced for membranes
containing NTA-DTDA, than for those containing NTA3-
DTDA. The apparent dissociation constants as determined
using the expression Kd=koff/kon, also were generally much
lower for membranes containing NTA3-DTDA than for mem-
branes containing NTA-DTDA. For example, at 1 AM B7.1 the
Kd were: 168T45104 s1 (fast) and 4.5T0.9104 s1
(slow)], and 279T37104 s1 (fast) and 13.0T3.2104 s1
(slow) for membranes containing NTA3-DTDA and NTA-
DTDA, respectively (Table 1). Moreover, at a B7.1-6H
concentration of 1 AM, the extent of the slow dissociation
component was ¨3.5-fold greater for NTA3-DTDA-containing
membranes, compared to membranes containing NTA-DTDA.
These findings indicate that B7.1-6H binds more stably and at
higher levels to membranes containing NTA3-DTDA, than to
membranes containing NTA-DTDA.
3.2. Targeting plasma membrane vesicles containing either
NTA3-DTDA or NTA-DTDA
In previous studies, we showed that the chelator-lipid NTA-
DTDA can be incorporated into tumor cell-derived PMV,
permitting the engraftment of 6His-tagged costimulatory
molecules onto vesicle surfaces for the development of tumor
vaccines [16]. The greater stability of 6His-tagged proteins
anchored onto membranes containing NTA3-DTDA, compared
to membranes containing NTA-DTDA, suggests that NTA3-
DTDA could have advantages for vaccine development. To
explore this possibility, P815 cell-derived PMV were modified
by incorporation of either NTA-DTDA or NTA3-DTDA, and
the modified PMV then engrafted with B7.1-6H and CD40-6H,
before incubation with the murine T cell clone D10, to assess
the binding of engrafted PMV to these cells by flow cytometry.
Preliminary binding experiments indicated that NTA3-
DTDA is also more potent than NTA-DTDA at promoting
the binding of B7.1 and CD40-engrafted PMV (PMV-B7-
CD40) to the murine T cell clone D10. In data not shown, near-
maximal binding of engrafted PMV to D10 cells was obtained
using PMV modified with POPC, NTA-DTDA and FITC-
DHPE (molar ratio 78:20:2), and with POPC, NTA3-DTDA
and FITC-DHPE (molar ratio 96:2:2). PMV modified with
either NTA-DTDA or NTA3-DTDA under these conditions,
and then engrafted with the control protein EPOR-6H (PMV-
EPOR) and incubated with D10 cells, resulted in the
fluorescence of the cells increasing to ¨3-fold above back-
ground irrespective of the chelator lipid used (Fig. 3).
Table 1
Binding constants for the interaction of B7.1-6H with membranes containing either NTA-DTDA or NTA3-DTDA
Protein (nM) kon (M
1 s1)104 koff (s1)104 Extent 9 (arc sT18%) T1/2 (min) Kd (nM)
NTA-DTDA
20 2.62T0.06 3.6T0.6 (fast) 3 31T5 14T3
0.10T0.03 (slow) 18 1155T346 0.38T0.10
50 12T2 (fast) 7 9.6T1.6 45T8
0.19T0.03 (slow) 53 608T96 0.72T0.20
100 20T2 (fast) 14 5.8T0.6 76T9
0.41T0.08 (slow) 82 281T55 1.56T0.34
250 39T1 (fast) 73 3.0T0.1 149T7
0.80T0.02 (slow) 94 144T4 3.0T0.1
500 58T3 (fast) 117 2.0T0.1 221T17
1.8T0.2 (slow) 108 64T9 6.9T1.1
1000 73T8 (fast) 157 1.6T0.2 279T37
3.4T0.8 (slow) 88 34T8 13.0T3.2
NTA3-DTDA
20 1.55T0.08 1.7T0.3 (fast) 2 68T12 11.0T2.9
<0.05 (slow) 42 ND ND
50 4.6T0.5 (fast) 4 25T3 29.7T5.6
0.06T0.01 (slow) 90 1925T322 0.4T0.1
100 8T1 (fast) 13 14.4T1.8 52T11
0.13T0.02 (slow) 142 887T204 0.8T0.2
250 13T2 (fast) 67 8.9T1.3 84T19
0.28T0.05 (slow) 206 412T74 1.8T0.4
500 20T2 (fast) 122 5.8T0.6 129T23
0.42T0.12 (slow) 288 275T80 2.7T1.0
1000 26T5 (fast) 148 4.4T0.1 168T45
0.70T0.08 (slow) 318 165T18 4.5T0.9
Experiments were performed by depositing membranes containing the carrier lipids DMPC and POPC plus either 10 mol% NTA-DTDA or 3.3 mol% NTA3-DTDA
into the test well of an IAsys biosensor cuvette, and then adding different concentrations of B7.1-6H in PBS (pH 7.4) (see Fig. 2). The binding and dissociation phase
for the interaction of B7.1-6H with each membrane was monitored with the biosensor for 5 and 20 min, respectively (as described in the legend to Fig. 2); and kinetic
constants were then determined by applying the ‘‘Fast Fit’’ program to the data (see text). The on-rates (kon) were obtained form the slope of the line of best fit after
plotting the binding data (kobs) for the interaction of B7.1-6H with membranes containing either NTA-DTDA or NTA3-DTDA, against the B7.1-6H concentration
(see Fig. 1C); off-rates (koff) were determined from the dissociation phase of the indicated interaction by fitting the data to a double exponential model which
calculated the koff and dissociation extent (for extrapolation to the baseline) for the fast and slow components of the dissociation phases. The apparent dissociation
constant (Kd) for each interaction was then determined using the relationship Kd=koff/kon. Each constant represents the meanTS.E.M.s obtained from 3 to 5
independent experiments; ND (Not determined).
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PMV-B7-CD40 containing NTA-DTDA exhibited a 17.5-fold
increase in fluorescence intensity, whereas cells incubated with
PMV-B7-CD40 containing NTA3-DTDA exhibited a 35-fold
increase in fluorescence intensity (Fig. 3). The results indicate
that even when the concentration of NTA3-DTDA is 10-fold
lower than that of NTA-DTDA, the level of PMV binding
promoted by NTA3-DTDA is twice that of NTA-DTDA. PMV
modified with POPC, NTA3-DTDA and FITC-DHPE at molar
ratio 96:2:2 (with tracer), or with POPC and NTA3-DTDA at
molar ratio 98:2 (without tracer), therefore, was used for all
subsequent experiments outlined below.
3.3. Plasma membrane vesicles engrafted with B7.1 and CD40
target T cells in vivo
The greater ability of NTA3-DTDA to promote binding of
engrafted PMV to cells in vitro led us to explore the
effectiveness with which NTA3-DTDA-modified PMV could
target T cells in vivo. Mice were injected into the hind footpad
with different liposomal preparations, being namely, conven-
tional liposomes (CL), stealth liposomes (SL) or PMV, all ofwhich contained NTA3-DTDA, and were engrafted with either
EPOR-6H (as control) or B7.1 plus CD40. Draining and non-
draining popliteal lymph nodes were removed 14 h after the
injection, and lymphocytes isolated from the nodes were
incubated with biotinylated CD3( mAb followed by streptavi-
din-PE, for analysis by flow cytometry.
Lymphocytes isolated from the draining and non-draining
lymph nodes of animals injected with control CL, SL or PMV
engrafted with EPOR-6H (not shown), and those isolated from
the non-draining lymph nodes of mice injected with CL, SL or
PMVengrafted with B7.1-6H and CD40-6H (Fig. 3, panels A–
C), all exhibited little or no increase in BODIPY-fluorescence.
Lymphocytes isolated from the draining lymph nodes of mice
injected with CL engrafted with B7.1-6H and CD40-6H, also
showed little, if any, increase in BODIPY-fluorescence (Fig. 4,
panel D). In contrast, lymphocytes isolated from the draining
lymph node of mice injected with B7.1-6H- and CD40-6H-
engrafted SL and PMV exhibited significant increases in
BODIPY-fluorescence (Fig. 4, panels E and F). Furthermore,
two-colour FACS analysis revealed that lymphocytes exhibit-
ing increased BODIPY-fluorescence also exhibited increased
CD3( mAb binding (Fig. 4, panels H and I). These data
Fig. 3. A comparison of the ability of NTA-DTDA and NTA3-DTDA to mediate binding of B7.1- and CD40-engrafted PMV to murine D10 cells. Activated D10
cells were incubated (1 h, 4 -C) separately with PMV containing FITC-DHPE as tracer plus either NTA-DTDA (20 mol%) or NTA3-DTDA (2 mol%), and engrafted
with either EPOR (PMV-EPOR) or with B7.1 and CD40 (PMV-B7-CD40), as indicated. The cells were then washed and analysed for FITC-fluorescence by flow
cytometry, with the fluorescence profiles reflecting binding of the NTA-DTDA- and NTA3-DTDA-modified PMV to the cells, as shown. The profile for PMV-EPOR
was similar for NTA-DTDA and NTA3-DTDA. Background fluorescence represents autofluorescence of the T cells. Each fluorescence profile is a representative
obtained from three separate experiments performed in duplicate.
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ically target T cells in vivo, and that for liposomes, the
targeting is critically dependent on the presence of the ‘‘stealth’’
or sterically stabilising lipid PE-PEG2000.
3.4. Cytokines can be incorporated with plasma membrane
vesicles
In previous studies, we showed that IL-2 can be incorporated
with NTA-DTDA-containing PMV with >95% efficiency [16].
In analogous studies, we assessed the efficiency of incorpora-
tion of IL-12, GM-CSF and IFN-g into NTA3-DTDA-contain-
ing PMV. Cytokine-containing liposomes were prepared and
fused with PMV (see Materials and methods), before subject-
ing the composite PMV to gel filtration, followed by an
analysis of the vesicle-incorporated and -unincorporated
cytokine fractions by SDS-PAGE (Fig. 5A). Densitometric
analysis of the resulting cytokine bands after western transfer
and ECL detection of the cytokine bands indicated that under
these conditions >85% of the GM-CSF and >75% of the IFN-g
was associated with the membrane vesicle fraction (Fig. 5B).
Attempts to quantify encapsulation of IL-12 were unsuccessful
due to poor biotinylation and detection of this cytokine by
ECL. In the functional studies below, therefore, IL-12 was
assumed to be incorporated to a level similar to IFN-g and
GM-CSF.
3.5. B7.1- and CD40-engrafted PMV containing NTA3-DTDA
stimulate T cell proliferation and cytolytic activity
To examine whether engrafted PMV containing NTA3-
DTDA and different cytokines could induce functional effects,
B7.1-CD40-engrafted PMV were incubated with splenic T cells
for assessment of T cell proliferation in vitro. As depicted in
Fig. 6, only low levels of [3H]-thymidine incorporation wasobserved in control cultures, incorporation being ¨4500 cpm
for cultures of T cells alone (T cells) and ¨6500 cpm for
cultures of T cells with PMV engrafted with the EPOR (PMV-
EPOR). A higher level of [3H]-thymidine incorporation was
observed when T cells were cultured with PMV engrafted with
EPOR and containing encapsulated IL-2 (PMV-EPOR-IL-2)
(¨12,500 cpm), GM-CSF (PMV-EPOR-GM-CSF) (¨11,500
cpm), IFN-g (PMV-EPOR-INF-g) (¨12,600 cpm), IL-12
(PMV-EPOR-IL-12) (¨12,700 cpm), and IL-2 and IL-12
(PMV-EPOR-IL-2-IL-12) (¨15,000 cpm). The incorporation
of [3H]-thymidine was increased to much higher levels,
however, in cultures of T cells and PMV bearing engrafted
B7.1 and CD40 (PMV-B7-CD40) (¨130,000 cpm), PMV
bearing engrafted B7.1 and CD40 and containing IL-2 (PMV-
B7-CD40-IL-2) (¨180,000 cpm), GM-CSF (PMV-B7-CD40-
GM-CSF) (¨148,000 cpm), IFN-g (PMV-B7-CD40-IFN-g)
(¨157,000 cpm), IL-12 (PMV-B7-CD40-IL-12) (¨219,000
cpm), and IL-2 and IL-12 (PMV-B7-CD40-IL-2-IL-12)
(¨330,000 cpm) (Fig. 6). The results indicate that PMV
containing cytokine and engrafted B7.1 and CD40 are
considerably more effective than control PMV, in stimulating
T cell proliferation.
Engrafted PMV containing NTA3-DTDA and cytokine also
were examined for their ability to stimulate a cytotoxic
response in a standard 51Cr release assay. As shown in Fig.
7, cells isolated from control mice immunised either with PBS,
or with EPOR-engrafted PMV that either did not contain
cytokine (PMV-EPOR) or that contained encapsulated cyto-
kines IL-2 and IL-12 (EPOR-IL-2-IL-12), induced only low
levels (4–13%) of lysis at all the effector/target ratios tested
(50, 25, 10, 5 and 1). Conversely, compared to T cells from
these control mice, the cytolytic activity of T cells isolated from
mice immunised with B7.1-CD40-engrafted PMV (PMV-B7-
CD40), or with B7.1-CD40-engrafted PMVencapsulating IL-2,
IL-12 or IL-2 plus IL-12, was 5-, or 7-, 7.6- and 8.1-fold
Fig. 4. Targeting of engrafted NTA3-DTDA-liposomes and PMV to T cells in vivo. NTA3-DTDA was incorporated into conventional liposomes (CL) lacking PE-
PEG2000, stealth liposomes (SL) containing PE-PEG2000 or modified PMV (PMV). Each liposome/membrane preparation was then engrafted with either EPOR-6H
or B7.1-6H plus CD40-6H, before being injected subcutaneously (hind footpad) into mice. After 14 h, the draining and non-draining popliteal lymph nodes were
removed, and lymphocytes isolated and stained with biotinylated-CD3( mAb followed by streptavidin-PE. The cells were then analysed for BODIPY- and PE-
fluorescence by flow cytometry, utilising the intrinsic label (1% BODIPY-PC) of the liposomes and PMV, and staining with streptavidin-PE (to identify CD3+ cells).
Panels A–C show dot plots of BODIPY-fluorescence vs. FSC for lymphocytes derived from the non-draining lymph nodes of mice injected with B7.1-C40-
engrafted CL, SL or PMV, respectively. Results for draining lymph nodes are shown in panels D–F. The corresponding BODIPY- vs. PE-fluorescence for
lymphocytes from draining lymph nodes are shown in panels G–I, respectively. Each plot is representative from two experiments.
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7). Similarly, the cytolytic activity of T cells for conditions
using B7.1-CD40-engrafted PMV encapsulating either GM-
CSF or IFN-g also were tested; for these conditions, the
increase in specific lysis induced was ¨6-fold above the
respective controls (data not shown). In parallel experiments,
only background levels of cell lysis were observed when
murine A20 cells were used as target cells (not shown),
indicating that the observed cytolytic responses are P815 cell-
specific.
3.6. Immunisation with engrafted PMV protects against tumor
challenge and induces regression of established tumors
To further establish the potential for engrafted PMVas tumor
vaccines, DBA/2J mice were immunised with B7.1-CD40-
engrafted PMV containing cytokine, and the mice then
monitored for tumor growth after challenge with the syngeneic
tumor. The data in Fig. 8A show that, relative to miceimmunised with PBS or EPOR-engrafted PMV containing IL-
2 and IL-12, mice immunised with B7.1-CD40-engrafted PMV
exhibited a slower rate of tumor growth, which was more
pronounced when the PMV also contained IL-2 and/or IL-12.
Thus, 7 weeks after tumor challenge, the mean tumor diameter
was 6.3T0.2 mm, 3.3T0.3 mm and 1.0T0.3 mm, for mice
immunised with B7.1-CD40-engrafted PMV, B7.1-CD40-
engrafted PMV containing either IL-2 or IL-12, and B7.1-
CD40-engrafted PMV containing IL-2 plus IL-12, respectively.
In contrast, control mice immunised with PBS or with EPOR-
engrafted PMV containing IL-2 plus IL-12 had a mean tumor
diameter of 13T0.5 mm or 11T0.5 mm, respectively (Fig. 8A).
At 12 weeks after tumor challenge, survival ranged from 0 to
15% for mice immunised with PBS or EPOR-engrafted PMV
containing cytokines, and 70–85% for mice immunised with
B7.1-CD40-engrafted PMV containing cytokines (Fig. 8B).
Immunisations with B7.1-CD40-engrafted PMV that contained
either GM-CSF or IFN-g also were carried out, but the anti-
tumor effects induced were less pronounced than those observed
Fig. 5. Engrafted PMV efficiently incorporate cytokines. Synthetic liposomes
containing either biotinylated GM-CSF or biotinylated IFN-g were fused with
PMV by sonication and treatment with PEG400. The composite vesicles were
purified by size-exclusion chromatography, with the vesicle-incorporated and
-unincorporated cytokine fractions being collected separately, and then
concentrated. (A) Shows result of ECL detection, with the bands reflecting
the cytokine in each fraction after reduced SDS-PAGE analysis, transfer of the
proteins onto nitrocellulose membrane, and then probing the membrane with
streptavidin-HRP. (B) Shows the relative intensity of the cytokine band
representing for each fraction the amount of cytokine relative to the total
cytokine used (as indicated). Densitometric analysis was carried out by scanning
the film after ECL detection and analysing the intensity of bands using NIH
Image 1.61 software.
Fig. 6. Stimulation of T cell proliferation by P815 cell-derived PMV
containing cytokines and engrafted with costimulatory molecules. Syngeneic
DBA/2J splenic T lymphocytes (1105) were incubated alone (T cells), o
separately with; control PMV engrafted with EPOR (PMV-EPOR); PMV
engrafted with EPOR and containing IL-2 (PMV-EPOR-IL-2), GM-CSF
(PMV-EPOR-GM-CSF), IFN-g (PMV-EPOR-IFN-g), IL-12 (PMV-EPOR-IL
12) or IL-2 plus IL-12 (PMV-EPOR-IL-2-IL-12); PMV engrafted with B7.1
and CD40 (PMV-B7-CD40); and PMV engrafted with B7.1 and CD40 and
containing IL-2 (PMV-B7-CD40-IL-2), GM-CSF (PMV-B7-CD40-GM-CSF)
IFN-g(PMV-B7-CD40-IFN-g), IL-12 (PMV-B7-CD40-IL-12), or IL-2 plus
IL-12 (PMV-B7-CD40-IL-2-IL-12). The cells were cultured for 4 days and
then pulsed with 1 ACi of [3H]-thymidine for 16–18 h, before harvesting and
measuring radioactivity to assess [3H]-thymidine incorporation. Results are
shown as counts per minute (cpm)TS.E.M.
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the immunisation of syngeneic mice with engrafted PMV
containing cytokines can inhibit tumor growth and prolong
survival of the animals after challenge with the native tumor.
To examine whether the engrafted PMV vaccine could
induce regression of the native tumor, separate groups of DBA/
2J mice were challenged by the injection of P815 cells
subcutaneously, and the mice then vaccinated three times at
1-week intervals with engrafted PMV containing cytokine, and
the mice in each group then monitored for tumor growth and
survival. The results show that, compared to control mice
immunised with EPOR-engrafted PMV containing cytokine,
mice immunised with B7.1-CD40-engrafted PMV containing
IL-2 and IL-12, exhibited a significant decrease in the rate of
tumor growth, followed by a regression in tumor size (Fig. 9A).
Eight weeks after tumor challenge, the mean tumor diameter
was 13.0T0.4 mm and 2.0T0.3 mm, for mice immunised with
PMV-EPOR-IL-2-IL-12, and PMV-B7-CD40-IL-2-IL-12, re-
spectively (Fig. 9B). At 16 weeks after tumor challenge,
survival range was 0–15% for mice immunised with PMV-
EPOR-IL-2-IL-12, and 60–75% for mice immunised with
PMV-B7-CD40-IL-2-IL-12 (Fig. 9B). These results indicatethat the immunisation of syngeneic mice with costimulator-
engrafted PMV containing incorporated IL-2 and IL-12 can
induce regression of pre-existing P815 tumors in vivo and
improve the survival of tumor bearing animals.
4. Discussion
The present work explored the binding properties of the
novel chelator lipid NTA3-DTDA when incorporated into lipid
membranes, and the potential for this lipid to be useful for the
anchoring of targeting molecules on liposomal membranes for
the development of cancer vaccines and/or immunotherapies.
The headgroup of NTA3-DTDA contains three NTA metal
chelating moieties, with each NTA being coupled to one of the
three COOH groups of a primary NTA-DTDA structure (see
Fig. 1). This has produced a lipid in which the hydrophilic
headgroup contains three NTA moieties in close proximity,
thereby facilitating co-operative interactions with 6His-tagged
proteins. In previous studies, utilising the IAsys biosensor, we
showed that the interaction of 6H-tagged proteins with NTA-
DTDA-containing membranes is significantly more stable
when the membrane contains a higher molar ratio of NTA-
DTDA to carrier lipid [24]. We envisaged, therefore, that the
use of a chelator lipid with a headgroup containing three NTAr
-
,
Fig. 7. Induction of tumor-specific cytotoxic responses in mice immunised with
costimulator-engrafted PMV containing cytokines. Mice were immunised
subcutaneously with PBS, or with: P815 cell-derived PMV engrafted with
EPOR (PMV-EPOR); PMV engrafted with EPOR and containing IL-2 plus
IL-12 (PMV-EPOR-IL-2-IL-12); PMV engrafted with B7.1 and CD40 (PMV-
B7-CD40); and PMV engrafted with B7.1 and CD40 and containing IL-2
(PMV-B7-CD40-IL-2), IL-12 (PMV-B7-CD40-IL-12), or IL-2 plus IL-12
(PMV-B7-CD40-IL-2-IL-12). After 14 days splenic T cells were isolated and
co-cultured with g-irradiated native P815 cells for 5 days before being
incubated for a further 6 h with 51Cr-labelled native P815 cell targets (at the
indicated E:T ratio) for determination of specific lysis in a standard 51Cr release
assay. Results are expressed as the percentage specific lysisTS.E.M. At 50:1
E:T ratio, *indicates specific lysis is significantly higher: (n =6, ***P <0.001)
than control mice immunised with either PBS or EPOR-engrafted PMV (with
or without cytokine); (n =6, **P <0.01) than mice immunised with
B7.1-CD40-engrafted PMV not containing cytokine.
Fig. 8. Anti-tumor responses in syngeneic mice immunised with costimulator-
engrafted PMV containing cytokines. Separate groups of mice (7 mice in each
group) were immunised subcutaneously with PBS, or with: P815 cell-derived
PMV engrafted with EPOR (PMV-EPOR); PMV engrafted with EPOR and
containing IL-2 plus IL-12 (PMV-EPOR-IL-2-IL-12); PMV engrafted with
B7.1 and CD40 (PMV-B7-CD40); and PMV engrafted with B7.1 and CD40
and containing IL-2 (PMV-B7-CD40-IL-2), IL-12 (PMV-B7-CD40-IL-12), or
IL-2 plus IL-12 (PMV-B7-CD40-IL-2-IL-12), as indicated. Two weeks after
vaccination the mice in each group were challenged by subcutaneous injection
of native P815 cells (1105), and the mice then monitored for tumor growth.
Each point in panel A represents the mean tumor diameter for each group of
mice as a function of time for the first 7 weeks. At week 7, *indicates
significance of tumor growth: (n =6, ***P <0.001) with respect to control mice
(immunised with either PBS, or with EPOR-engrafted PMV with or without
cytokine); (n =6, **P <0.01) with respect to mice immunised with B7.1-CD40-
engrafted PMV not containing cytokine; (n =6, *P <0.05) with respect to B7.1-
CD40-engrafted PMV containing either IL-2 or IL-12. The data in panel B
show the percentage survival of the animals with time.
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DTDA) would have advantages in applications for the study of
molecular interactions on lipid membranes, as well as for the
development of vaccines and/or targeted liposomal agents.
An analysis of the binding of B7.1-6H to membranes
containing either NTA-DTDA or NTA3-DTDA, with the IAsys
biosensor revealed that B7.1-6H interacts more stably with
membranes containing NTA3-DTDA. For these studies a 3-fold
higher concentration of NTA-DTDA compared to NTA3-
DTDA was used so as to compare binding to the same total
number of NTA moieties on the deposited membranes. The
results show that the on-rate for binding of B7.1-6His was
faster for NTA-DTDA-membranes (2.62T0.06104 M1 s1),
than for NTA3-DTDA-membranes (1.55T0.08104 M1 s1).
However, binding to NTA3-DTDA-membranes generally
exhibited a slower off-rate (i.e., fast and slow components)
and a 1- to 3-fold lower Kd, at all of the B7.1-6His
concentrations tested (see Fig. 2 and Table 1). The results
demonstrate that, even when the total number of NTA moieties
on the membrane is the same, the binding of His-tagged
proteins to NTA3-DTDA-membranes is markedly more stable
than that to NTA-DTDA-membranes.
A detailed analysis of the nature of the interaction of 6H-
tagged proteins with NTA3-DTDA, was considered beyond the
scope of the present work. However, each NTA moiety can
bind one divalent metal ion (Ni2+), and each Ni-NTA can, in
turn, interact with two successive histidine residues. The
greater stability of 6H-tagged proteins anchored onto NTA3-DTDA-membranes, therefore, is likely to be due to a higher
local density of Ni-NTA moieties, compared to NTA-DTDA-
membranes. Since each molecule of NTA3-DTDA has three
Ni-NTA groups, all six histidine residues can potentially
interact simultaneously with one Ni-NTA3-DTDA molecule,
facilitating co-operative interactions and stable binding of the
6H-tagged protein. Each Ni-NTA-DTDA, on the other hand,
can simultaneously interact with only two successive His
residues, thereby enabling stable interactions with 6H-tagged
proteins to occur only at high NTA-DTDA concentrations.
Previously, we showed that NTA-DTDA can be incorporated
into liposomes and PMV for engraftment of 6H-tagged proteins
for liposome targeting and vaccine development [16]. To
determine whether NTA3-DTDA also can be used to engraft
Fig. 9. Immunisation of syngeneic mice with costimulator-engrafted PMV
containing IL-2 and IL-12 induces regression of established tumors. Separate
groups of mice were injected subcutaneously with 1105 native P815 cells. Two
weeks after injection the mice were immunised subcutaneously with either P815
cell-derived control PMV engrafted with EPOR containing IL-2 plus IL-12
(PMV-EPOR-IL-2-IL-12); or PMVengrafted with B7.1 and CD40 and contain-
ing IL-2 and IL-12 (PMV-B7-CD40-IL-2-IL-12) as indicated. The mice in each
group were then monitored for tumor growth. The data in panel A show the mean
tumor diameter of each group of mice as a function of time for the first 8 weeks.
The data in panel B show the percentage survival of the animals with time.
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ability of liposomal membranes containing NTA3-DTDA and
engrafted with B7.1 and CD40, to interact specifically with
cells. For these and subsequent functional studies, we used
concentrations (molar ratios) of NTA3-DTDA that were 10-fold
lower than those used for NTA-DTDA. In vitro studies in which
B7.1-CD40-engrafted PMV derived from P815 tumor cells
were incubated with D10 cells in vitro showed that the engrafted
PMV bound T cells in a receptor–ligand-specific manner (Fig.
3). Importantly, the administration of B7.1-CD40-engrafted
PMV and stealth liposomes to mice by hind footpad injection
resulted in an increased number of labelled T cells being
isolated in the draining popliteal lymph node, indicating that
these can target T cells in vivo. Interestingly, no targeting was
observed with conventional liposomes that lack PE-PEG2000
(Fig. 4), suggesting that the inclusion of this ‘‘stealth’’ lipid is
crucial for effective targeting of liposomes in vivo, presumably
by reducing non-specific binding to other blood components.Consistent with the observed stronger interaction of B7.1-
6H with NTA3-DTDA-containing membranes (Fig. 2, Table 1),
the results show that B7.1-CD40-engrafted liposomal mem-
branes containing NTA3-DTDA also are very effective at
mediating specific binding to T cells in vitro and in vivo (Figs.
3 and 4). Importantly, B7.1 and CD40 once engrafted onto
PMV via incorporated NTA3-DTDA, also could be shown to
induce functional effects in assays of syngeneic T cell
proliferation and cytolytic activity. The large increases in T
cell proliferation observed (Fig. 6) suggests that in these studies
a substantial component of the proliferation induced is due to
the mitogenic effect of cross-linking the CD28 molecule on T
cells by liposome-engrafted CD80. However, since vaccination
of animals with CD80-bearing PMV containing IL-2 and IL-
12, does not induce significant specific cytolytic responses or
offer protection against growth of the P815 tumor (or provide
survival advantage to mice) when the PMVs used in the
immunisation are derived from the EL-4 lymphoma instead of
P815 cells (not shown), the results demonstrate that the anti-
tumor effect of the vaccine is antigen-specific.
Considerable evidence suggests that the stimulatory capac-
ity of a vaccine may depend on the presence of cytokines. In
the present work, cytokines were encapsulated into NTA3-
DTDA-containing PMV engrafted with costimulatory mole-
cules, thus permitting the simultaneous delivery of antigen,
costimulatory signals and cytokine to T cells. For encapsulation
into PMV, cytokines were first incorporated into synthetic
liposomes containing NTA3-DTDA, and the liposomes then
fused with P815-derived PMV. Our results show that encap-
sulation of IFN-g and GM-CSF into PMV in this way occurs
with high efficiency (>75%–85%, Fig. 5), similar to that of IL-
2 [16]; significant incorporation of IL-12 also could be
demonstrated by functional studies (Figs. 7 and 8). While IL-
2, IL-12, GM-CSF and IFN-g all have been purported to
exhibit beneficial effects in the treatment of tumors [12,18,19],
in the present work strong anti-tumor responses were induced
by costimulator-engrafted PMV containing IL-2 and/or IL-12,
with those containing GM-CSF and IFN-g inducing a smaller
effect. Interestingly, costimulator-engrafted PMV containing
both IL-2 and IL-12 induced additive effects on T cell
proliferation (Fig. 6), and inhibited tumor growth and
prolonged survival of syngeneic mice challenged with the
native P815 tumor (Fig. 8). Importantly, the immunisation of
tumor-bearing mice with B7.1-CD40-engrafted PMV contain-
ing IL-2 and IL-12 could induced regression of established
tumors and prolong survival of these animals (Fig. 9). These
observations are consistent with an ability of B7.1-CD40-
engrafted PMV to interact specifically with T cells (Figs. 3 and
4), and with the reported ability of IL-2 and IL-12 to stimulate
T cell activation and cytolytic activity in vivo [11].
A major finding from the present work is that the novel lipid
NTA3-DTDA can be used to anchor 6H-tagged proteins with
greater stability and effectiveness than NTA-DTDA. Thus,
while achieving responses which are directly comparable and
essentially the same as those previously obtained with NTA-
DTDA (Ref. [16] see Figs. 6 and 7), the present work shows
that the induction of tumor-specific cytotoxic responses (Fig.
C.L. van Broekhoven, J.G. Altin / Biochimica et Biophysica Acta 1716 (2005) 104–116 1157), the inhibition of tumor growth (Fig. 8A), and the effect on
prolongation of survival (Fig. 8B), can all be achieved at
concentrations of NTA3-DTDA that are 10-fold lower than
those previously required for NTA-DTDA [16]. These results
are consistent with the binding data presented in Figs. 1–3 and
Table 1, which show that the stability of membrane-anchored
CD80 is much greater for NTA3-DTDA than for NTA-
DTDA—even when the NTA-DTDA is at a 3-fold higher
concentration. The findings thus demonstrate that NTA3-
DTDA is potentially a more useful lipid for both the study of
molecular interactions on model membranes, and the develop-
ment of targeted membranes and liposomal agents for the
development of tumor vaccines and immunotherapies. Consis-
tent with our previous findings with NTA-DTDA [16], tumor
cell-derived PMV containing NTA3-DTDA, allow engraftment
of costimulatory molecules onto the surface of the PMV, and
encapsulation of cytokine, for simultaneous delivery of PMV-
associated antigens, costimulatory signals and cytokines. Thus,
effective responses against the P815 tumor can be generated in
mice immunised with PMV containing encapsulated cytokines
and bearing engrafted costimulatory molecules. In the present
work, we also show that the vaccination of animals subsequent
to their inoculation with the P815 tumor can induce a slowing
of the rate of growth, followed by a regression of tumor
growth, prolonging survival of the animals (Fig. 9). The results
show that vesicle-engrafted B7.1 and CD40 coupled via NTA3-
DTDA also are functionally active, that the encapsulated
cytokines can provide concomitant stimulation, and that
antigens on the modified PMV can still stimulate anti-tumor
responses in a syngeneic system.
The modified PMV described herein offer several distinct
advantages over other targeted liposome systems, or the use of
immunostimulatory-gene transfected tumor cells in the devel-
opment of anti-tumor vaccines. Firstly, PMV may be prepared
from tumor tissue and stored frozen until required, avoiding the
need to establish primary cultures of tumor cells for transfec-
tion [28]. Secondly, modification of the PMV can be achieved
in a relatively short period of time (¨2 h), unlike the genetic
transfection of cells [29,30]. The modified PMV can be
engrafted with many different His-tagged proteins simulta-
neously, and encapsulate a number of different cytokine(s),
whereas multiple transfections and expression of different
molecules simultaneously can be difficult to achieve in practice
[31]. The results show that tumor-derived PMV modified in
this way can target T cells in vivo, stimulating specific anti-
tumor immune responses and regression of established tumors
in the P815 model. It is envisaged that the system described
could be adapted to target a number of agents to various cells in
vivo, as for example the delivery of antigens to dendritic cells
for the induction or suppression of immune responses [32].
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